214 related articles for article (PubMed ID: 34332092)
21. Drugging Undruggable Molecular Cancer Targets.
Lazo JS; Sharlow ER
Annu Rev Pharmacol Toxicol; 2016; 56():23-40. PubMed ID: 26527069
[TBL] [Abstract][Full Text] [Related]
22. Drugging "undruggable" genes for cancer treatment: Are we making progress?
Duffy MJ; Crown J
Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
[TBL] [Abstract][Full Text] [Related]
23. The Use of Methods of Computer-Aided Drug Discovery in the Development of Topoisomerase II Inhibitors: Applications and Future Directions.
Radaeva M; Dong X; Cherkasov A
J Chem Inf Model; 2020 Aug; 60(8):3703-3721. PubMed ID: 32687346
[TBL] [Abstract][Full Text] [Related]
24. Targeting Transcription Factors for Cancer Treatment.
Lambert M; Jambon S; Depauw S; David-Cordonnier MH
Molecules; 2018 Jun; 23(6):. PubMed ID: 29921764
[TBL] [Abstract][Full Text] [Related]
25. Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.
Santoni M; Massari F; Del Re M; Ciccarese C; Piva F; Principato G; Montironi R; Santini D; Danesi R; Tortora G; Cascinu S
Expert Opin Investig Drugs; 2015 Jun; 24(6):809-24. PubMed ID: 25746129
[TBL] [Abstract][Full Text] [Related]
26. BAG1L: a promising therapeutic target for androgen receptor-dependent prostate cancer.
Lee II; Kuznik NC; Rottenberg JT; Brown M; Cato ACB
J Mol Endocrinol; 2019 May; 62(4):R289-R299. PubMed ID: 30913537
[TBL] [Abstract][Full Text] [Related]
27. Synthetic lethality as an engine for cancer drug target discovery.
Huang A; Garraway LA; Ashworth A; Weber B
Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
[TBL] [Abstract][Full Text] [Related]
28. Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.
Singh S; Pandey VP; Yadav K; Yadav A; Dwivedi UN
Curr Protein Pept Sci; 2020; 21(11):1103-1142. PubMed ID: 32951576
[TBL] [Abstract][Full Text] [Related]
29. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
30. Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents.
Chou CC; Salunke SB; Kulp SK; Chen CS
J Cell Biochem; 2014 Apr; 115(4):611-24. PubMed ID: 24166934
[TBL] [Abstract][Full Text] [Related]
31. Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites.
Madison BJ; Clark KA; Bhachech N; Hollenhorst PC; Graves BJ; Currie SL
J Biol Chem; 2018 Nov; 293(48):18624-18635. PubMed ID: 30315111
[TBL] [Abstract][Full Text] [Related]
32. Drug discovery with engineered zinc-finger proteins.
Jamieson AC; Miller JC; Pabo CO
Nat Rev Drug Discov; 2003 May; 2(5):361-8. PubMed ID: 12750739
[TBL] [Abstract][Full Text] [Related]
33. Rational, computer-enabled peptide drug design: principles, methods, applications and future directions.
Diller DJ; Swanson J; Bayden AS; Jarosinski M; Audie J
Future Med Chem; 2015; 7(16):2173-93. PubMed ID: 26510691
[TBL] [Abstract][Full Text] [Related]
34. ETS transcription factors as emerging drug targets in cancer.
Hsing M; Wang Y; Rennie PS; Cox ME; Cherkasov A
Med Res Rev; 2020 Jan; 40(1):413-430. PubMed ID: 30927317
[TBL] [Abstract][Full Text] [Related]
35. Drug Repositioning Using Computer-aided Drug Design (CADD).
Rawat S; Subramaniam K; Subramanian SK; Subbarayan S; Dhanabalan S; Chidambaram SKM; Stalin B; Roy A; Nagaprasad N; Aruna M; Tesfaye JL; Badassa B; Krishnaraj R
Curr Pharm Biotechnol; 2024; 25(3):301-312. PubMed ID: 37605405
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel extracellular signal-regulated kinase docking domain inhibitors.
Hancock CN; Macias A; Lee EK; Yu SY; Mackerell AD; Shapiro P
J Med Chem; 2005 Jul; 48(14):4586-95. PubMed ID: 15999996
[TBL] [Abstract][Full Text] [Related]
37. MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity
Son DJ; Zheng J; Jung YY; Hwang CJ; Lee HP; Woo JR; Baek SY; Ham YW; Kang MW; Shong M; Kweon GR; Song MJ; Jung JK; Han SB; Kim BY; Yoon DY; Choi BY; Hong JT
Theranostics; 2017; 7(18):4632-4642. PubMed ID: 29158850
[No Abstract] [Full Text] [Related]
38. STAT proteins: novel molecular targets for cancer drug discovery.
Turkson J; Jove R
Oncogene; 2000 Dec; 19(56):6613-26. PubMed ID: 11426647
[TBL] [Abstract][Full Text] [Related]
39. Novel anticancer strategy aimed at targeting shelterin complexes by the induction of structural changes in telomeric DNA: hitting two birds with one stone.
Bidzinska J; Baginski M; Skladanowski A
Curr Cancer Drug Targets; 2014; 14(2):201-16. PubMed ID: 24443969
[TBL] [Abstract][Full Text] [Related]
40. Use of transcription factors as agents and targets for drug development.
Smith LM; Birrer MJ
Oncology (Williston Park); 1996 Oct; 10(10):1532-8; discussion 1541-2. PubMed ID: 8905845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
